News from avidity biosciences, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 07, 2022, 06:00 ET Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Sep 01, 2022, 09:05 ET Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 09, 2022, 16:05 ET Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 02, 2022, 08:00 ET Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Jun 17, 2022, 08:00 ET Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Jun 09, 2022, 09:00 ET Avidity Biosciences Announces Upcoming Presentations at the 29th Annual FSHD Society International Research Congress

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

May 10, 2022, 16:05 ET Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Apr 05, 2022, 09:00 ET Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Mar 29, 2022, 09:00 ET Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Mar 07, 2022, 09:00 ET Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Mar 01, 2022, 16:05 ET Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Feb 28, 2022, 09:00 ET Avidity Biosciences Honors Rare Disease Day®

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Feb 23, 2022, 09:00 ET Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Feb 11, 2022, 16:05 ET Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Dec 09, 2021, 09:00 ET Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Nov 09, 2021, 16:05 ET Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)

Nov 04, 2021, 09:00 ET Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Nov 02, 2021, 16:05 ET Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Oct 18, 2021, 09:00 ET FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 31, 2021, 09:30 ET Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (NASDAQ: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 25, 2021, 16:05 ET Avidity Biosciences Announces Changes to its Board of Directors

Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 24, 2021, 08:30 ET European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 16, 2021, 08:30 ET Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 09, 2021, 16:05 ET Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Aug 03, 2021, 21:16 ET Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...